Herbert Skip Virgin
2020
In 2020, Herbert Skip Virgin earned a total compensation of $1.1M as Executive Vice President, Research and Chief Scientific Officer at Vir Biotechnology, a 44% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $374,311 |
|---|---|
| Salary | $636,525 |
| Other | $95,400 |
| Total | $1,106,236 |
Virgin received $636.5K in salary, accounting for 58% of the total pay in 2020.
Virgin also received $374.3K in non-equity incentive plan and $95.4K in other compensation.
Rankings
In 2020, Herbert Skip Virgin's compensation ranked 8,205th out of 13,090 executives tracked by ExecPay. In other words, Virgin earned more than 37.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 8,205 out of 13,090 | 37th |
Division Manufacturing | 3,481 out of 5,620 | 38th |
Major group Chemicals And Allied Products | 1,404 out of 2,253 | 38th |
Industry group Drugs | 1,222 out of 1,953 | 37th |
Industry Biological Products, Except Diagnostic Substances | 287 out of 411 | 30th |
Source: SEC filing on April 6, 2021.
Virgin's colleagues
We found four more compensation records of executives who worked with Herbert Skip Virgin at Vir Biotechnology in 2020.